Salute e Benessere
Soterios Pharma Announces Positive Topline Results from Phase II Study of STS-01 in the Treatment of Mild / Moderate Alopecia Areata
Arash Mostaghini, Associate Professor of Dermatology at Brigham & Women's Hospital, said,
"These results are extremely encouraging. They validate the potential for STS-01 to provide mild-to- moderate alopecia sufferers with a safe and effective treatment for this debilitating condition. I am also excited by the prospect of targeting total hair regrowth in this patient group."
Mild / moderate alopecia areata (less than 50% hair loss / SALT score <50), represents over half of the 800,000 AA patients in the US and is associated with a significant disease burden, including depression and anxiety. The impact on quality of life for mild / moderate patients is equivalent to those with severe AA and yet no approved therapies exist for these patients.
David Fleet , CEO of Soterios Pharma, said, "This data gives us clarity and confidence in moving into late-stage clinical development for this product. We thank all the patients, investigators and healthcare staff who participated in this study."
Soterios Pharma is a UK-based clinical-stage life sciences company, which is focused on developing and commercialising medicines for dermatology diseases with major unmet needs. https://www.soteriospharma.com
The randomised, placebo-controlled, multi-dose Phase II trial evaluated the safety and efficacy of STS-01 in the treatment of mild / moderate AA when applied for 24 weeks. A total of 158 participants were randomised to receive one of four doses of STS-01 (0.25%, 0.5%, 1% or 2%) or placebo, with effect being measured based on improvement in the SALT score.
The product builds on a mechanism with a well-established safety profile in dermatology, and works through modulating the inflammatory response and the proliferation of T-cells by disruption of the signalling pathways. There is extensive preclinical and clinical evidence to support its efficacy and safety profile in AA.
Mark Brimble
info@soteriospharma.com
View original content:https://www.prnewswire.co.uk/news-releases/soterios-pharma-announces-positive-topline-results-from-phase-ii-study-of-sts-01-in-the-treatment-of-mild--moderate-alopecia-areata-302157485.html